Key Takeaways
- Record quarter, one-time noise: Revenue hit a 10-quarter high of ~₹640 crores, but a ₹24 cr onerous-contract provision, a ₹34 cr notional FX loss, and EDQM remediation costs masked the underlying operating momentum.
- Swiss late-phase mix drove the beat: Carbogen Amcis revenue grew ~10% YoY and EBITDA margin expanded to ~22%, powered by high-value Phase III development work that also pulled consolidated COGS well below its 18–20% norm.
- India is the margin unlock for FY24: India NCE API grew 54% over nine months but stayed EBITDA-negative on one-off EDQM costs; management expects Bavla normalcy in Q1 FY24 and India revenue up 15–20% next year, which would lift group margins significantly.
- France and ADC expansions are now live: The French injectable facility was inaugurated and authorized, with the first order booked for June; the Swiss ADC expansion for a Japanese customer completes on track and starts contributing in H1 FY24.
- What to watch next quarter: Whether the EDQM reinspection clears on schedule, the pace of European cost pass-through to customers, and any sign that the biotech funding slowdown is reaching the development pipeline.
Carbogen Amcis: The Quarter's Engine
- Late-phase development surge: Q3 benefited from a high-value Phase III development project executed in the Swiss entity, which carries much higher margins than the typical mix and pulled consolidated COGS below the 18–20% normalized run rate.
- Pipeline depth: The development project pipeline inside Carbogen Amcis crossed CHF 10 crore, reaching CHF 11.4 crore, representing more than a year of work at current capacity, which management called "extremely healthy."
- ADC expansion on track: The Bubendorf facility extension for a specific Japanese customer's ADC projects is completing on time and on budget, with contribution starting in the second quarter of the next fiscal year.
- Swiss wage inflation manageable: Employee cost inflation in Switzerland is expected around 2.8–3% for FY24, a headwind the company appears comfortable absorbing within its margin trajectory.
Pascal Villemagne: "Our current development project pipeline is also extremely healthy because we are above CHF 10 crore of development project within Carbogen Amcis. We are reaching CHF 11.4 crore now, which represents more than a year of work for all the value at Carbogen Amcis."
One-Time Costs That Distorted the Quarter
- Onerous contracts provision: A ₹24 crores provision was booked in Carbogen Amcis Switzerland under a conservative policy where cost overruns are anticipated on development projects; some of this could be relieved later depending on percentage of completion and customer negotiations.
- Notional FX loss: A ₹34 crores foreign exchange loss arose because a large US-dollar receivable balance at the Swiss entity had to be restated into Swiss francs for balance-sheet purposes and then into INR for consolidation, with hedges struck at lower rates than spot; some may reverse if exchange rates move favorably.
- EDQM remediation costs: India operations absorbed ~₹7–7.5 cr of one-time EDQM-related expenses in Q3 (and ~₹12 cr in Q2), the primary reason India NCE API stayed EBITDA-negative despite strong revenue growth.
- Energy cost spike: European energy costs rose ~50% YoY for the nine-month period (₹43 cr to ₹66 cr) and from ~₹15 cr to ~₹21 cr in the quarter, with a time lag in passing increases to customers that management says it has now begun to close.
- French facility pre-revenue costs: The new French greenfield site is carrying significant fixed costs for staffing, energy, and consumables tied to qualification and validation, ahead of any revenue generation.
India: The Margin Recovery Story
- Revenue growth intact, profitability delayed: India NCE API delivered 54% nine-month growth to ₹171 crores and Q3 revenue of ₹46 crores (vs ₹39.6 cr YoY), but the EDQM overhang kept the segment EBITDA-negative; India Quats and Generics grew 16% over nine months with a ~7.3% EBITDA margin.
- Bavla restoration timeline: The company has triggered the EDQM reinspection and expects it per regulatory timelines, with normalcy at Bavla restored in Q1 of the next fiscal year; a better sense of FY24 will emerge once clearance is received and the company moves into Q4.
- Conservative FY24 India target: Management expects India facilities (Bavla and Naroda) to deliver revenue at least 15–20% higher than the FY23 exit run rate, on a conservative basis, and as India comes back on track, group-level margins should increase significantly.
- CAPEX mostly maintenance: No major greenfield or large brownfield projects are planned near-term; maintenance CAPEX is expected at ~₹300-odd crores per year for the next two financial years, with ~₹500-odd crores total over 2–2.5 years including India water purification and ETP upgrades.
Harshil Dalal: "We do expect that the next year, we should have the India facilities do revenue, which is at least 15% to 20% more than what it would do by the end of this financial year. And this is obviously on a conservative basis."
France Facility: Live and Booking Orders
- Inaugurated and authorized: The new French greenfield facility was inaugurated the Friday before the call and has received official authorization from the French authority to open as a pharmaceutical site.
- First order secured: The first order has been booked and is to be manufactured by June, following completion of the major field test proving sterile-condition operations; qualification and validation continue in the coming weeks.
- FY24 revenue target: The business plan targets at least CHF 1.5 crores of revenue in FY24, with full two-shift capacity planned at EUR 3 crores; management described the unit as a "highly sophisticated injectable" facility from which "very decent revenue" should start flowing next fiscal year.
- Customer discussions underway: The company is in discussions with several customers to implement new projects and needs commitments in writing; the facility's ramp-up is a key near-term trigger already achieved.
Pascal Villemagne: "Our business plan has been clear. Next year, we want to reach at least CHF1.5 crore revenue for that facility. Top line and when that facility is going to run with two-shift system, we plan to reach EUR3 crore for that unit."
European Cost Pressures and the Pass-Through Lag
- Energy costs up ~50%: Energy costs rose from ~₹15 cr to ~₹21 cr in the quarter and from ₹43 cr to ₹66 cr over nine months, compressing margins across the European operations.
- Dutch margins squeezed: The Dutch business saw a significant revenue increase in Q3 as customer orders concentrated in the second half, but margins remained under pressure at ~17% due to elevated raw material prices.
- Pass-through process started: Management has begun passing increased European costs (energy, raw materials, employee costs from higher inflation) to customers; once the time lag is overcome, margins should return to earlier levels.
- Raw material relief expected: Raw material prices in the Netherlands are expected to come down in the course of the next financial year, and development efforts on the products business should also help improve margins.
Biotech Funding: Comfortable for Now, Unclear Beyond
- Funding still above pre-COVID levels: Venture capital investment in biotech has dropped from COVID peaks but remains quite high compared to 2019; the company has not yet suffered from the funding slowdown and is comfortable for the next fiscal year.
- Beyond FY24 is opaque: Management acknowledged that beyond the next fiscal year, it is "very difficult to predict" how the funding environment will affect the development pipeline.
- Receivables protected by prepayments: Development projects require ~30% prepayment before work begins, limiting collection risk even if the funding environment tightens; no strain has been seen on receivable collections.
Pascal Villemagne: "As far as time being, we haven't suffered from that. We still have some pipeline of products, and we are quite comfortable for the next fiscal year. Beyond that, it's obviously very difficult to predict."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| EDQM normalcy at Bavla | Bavla should commence normal operations; reinspection triggered and expected per regulatory timelines | Q1 FY24 |
| India revenue growth | India facilities (Bavla + Naroda) to deliver revenue at least 15–20% above FY23 exit, on a conservative basis | FY24 |
| Group margin expansion | Margins to increase significantly as India operations come back on track and European cost pass-through takes effect | Starting FY24 |
| French facility first revenue | First order booked, to be manufactured by June; FY24 target of at least CHF 1.5 cr revenue | June 2023 / FY24 |
| Swiss ADC expansion contribution | Bubendorf ADC extension for Japanese customer to start contributing | H1 FY24 (second quarter) |
| FY24 revenue growth | Revenue expected to grow 12–14% | FY24 |
| FY24 EBITDA growth | EBITDA growth expected at a much higher rate than revenue growth, aided by India EDQM base-effect normalization | FY24 |
| Maintenance CAPEX | ~₹300-odd crores per year; ~₹500-odd crores total over 2–2.5 years including India upgrades | Next 2–2.5 years |
Key Metrics
| Metric | Q3 FY23 |
|---|---|
| Consolidated revenue | ₹640 cr, best quarter in the last 10 quarters |
| 9M FY23 consolidated revenue | ₹1,794 cr |
| Consolidated EBITDA | ₹115 cr, 18% margin |
| 9M FY23 consolidated EBITDA | ₹287.5 cr, ~16% margin |
| Profit before tax | ₹45.6 cr, compared to ₹38.4 cr in Q3 FY22 |
| 9M FY23 profit before tax | ₹33 cr |
| Carbogen Amcis segment revenue | ₹462 cr, +10% YoY for Q3; +16% for 9M |
| Carbogen Amcis segment EBITDA margin | ~22% for Q3, compared to 20% in Q3 FY22; ~19% for 9M vs 20% in 9M FY22 |
| India NCE API revenue | ₹46 cr, compared to ₹39.6 cr in Q3 FY22 |
| India Quats and Generics revenue | ~₹49 cr, compared to ₹46.5 cr in Q3 FY22 |
| India Quats and Generics EBITDA margin | ~7.3% |
| Dutch business EBITDA margin | ~17% |
| FY24 revenue growth expectation | 12% to 14%; EBITDA growth expected to be much higher |
| Carbogen Amcis development project pipeline | CHF 11.4 cr, above CHF 10 cr |
| Provision for onerous contracts | ₹24 cr booked in Q3 |
| Foreign exchange loss | ₹34 cr booked in Q3 |
| Finance cost | ~₹22 cr, including forex loss of ~₹3.5 cr |
| Depreciation and amortization | ~₹50 cr, compared to ₹75 cr in Q3 FY22; goodwill amortization period extended from 15 to 22 years, reducing annual P&L charge by almost 50% from ₹89 cr |
| Energy cost | ~₹21 cr, compared to ~₹15 cr in Q3 FY22; 9M FY23 energy cost ₹66 cr, up almost 50% YoY |
| EDQM one-time expense | ₹7–7.5 cr in Q3, compared to ~₹12 cr in Q2 |
| CAPEX guidance | ~₹300-odd cr per year for next 2 financial years, total ~₹500-odd cr over 2–2.5 years, mostly maintenance CAPEX |
| French facility FY24 revenue target | at least CHF 1.5 cr; full two-shift capacity target EUR 3 cr |
| Swiss wage inflation expectation | around 2.8% to 3% for FY24 |